Congo red analogues as potential anti-prion agents

Farmaco

Volumn 58, Issue 9, 2003, Pages 929-937

  Villa, Stefania ^a   Cignarella, Giorgio ^a   Barlocco, Daniela ^a   Gervasoni, Marco ^a   Carcassola, Gabriella ^a   Giannino, Laura ^a   Mantegazza, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti prion molecules; Congo red; Transmissible spongiform encephalopathies (TSE)

Indexed keywords

1 AMINO 4 SULFONIC ACID 5,6,7,8 TETRAHYDRONAPHTHALENE; 1,2 DIAMINO 5,6,7,8 TETRAHYDRONAPHTHALENE; 1,2 DIAMINONAPHTHALENE; 3,4 DIAMINONAPHTHALENE 1 CARBOXYLIC ACID; 3,4 DIAMINONAPHTHALENE 1 SULFONAMIDE; 3,4 DIAMINONAPHTHALENE 1 SULFONIC ACID; CONGO RED; PRION PROTEIN; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CHEMICAL INTERACTION; CONTROLLED STUDY; DISEASE COURSE; ELECTRIC POTENTIAL; INCUBATION TIME; MOUSE; NEUROBLASTOMA; NONHUMAN; PATHOGENICITY; PRION DISEASE;

EID: 0141788017     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(03)00151-4     Document Type: Article

References (16)

1. Müller W.E.G., Laplanche J.L., Ushijima H., Schroder H.C. Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech. Ageing Dev. 116:2000;193-218.
2. Will R.G., Ironside J.W., Zeidler M., Cousens S.N., Estibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A., Smith A. New variant of Creutzfeld-Jakob disease in the UK. Lancet. 347:1996;921-925.
3. Bruce M.E., Will R.G., Ironside J.W., McConnell I., Drummond D., Suttie A., McCardle L., Chree A., Hope J., Birkett C., Cousens S., Fraser H., Bostock C.J. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 389:1997;498-501.
4. Scott M.R., Will R., Ironside J., Nguyen H.O., Tremblay P., DeArmond S.J., Prusiner S.B. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc. Natl. Acad. Sci. 96:(26):1999;15 137-15 142.
5. Soto C., Kascsak R.J., Saborio G.P., Aucouturier P., Wisniewski T., Prelli F., Kascsak R., Mendez E., Harris D.A., Ironside J., Tagliavini F., Carp R.I. Frangione B reversion of prion protein conformational changes by synthetic [beta]-sheet breaker peptides. Lancet. 355:2000;192-197.
6. Souan L., Tal Y., Felling Y., Cohen I.R., Taraboulos A., Mor F. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. Immunol. 31:2001;2338-2346.
7. sc in vitro. J. Mol. Biol. 300:2000;1309-1322.
8. Milhavet O., Mange A., Casanova D., Lehmann S. Effect of Congo red on wild-type and mutated prion proteins in cultured cells. J. Neurochem. 74:2000;222-230.
9. Caspi S., Halimi M., Yanai A., Sasson S.B., Taraboulos A., Gabizon R. The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem. 273:1998;3484-3489.
10. Demaimay R., Harper J., Gordon H., Weaver D., Chesebro B., Caughey B. Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J. Neurochem. 71:1998;2534-2541.
11. Das K.M., Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinetics. 1:1976;406-425.
12. Tan Ghee T., Wickramasinghe Anura, Verma Sandeep, et al. Potential anti-AIDS naphthalenesulfonic acid derivatives. Synthesis and inhibition of HIV-1 induced cytopathogenesis and HIV-1 and HIV-2 reverse transcriptase activities. J. Med. Chem. 35:1992;4846-4853.
13. Nakayama Toyoo, Okutome Toshiyuki, Matsui Ryoji, Kurumi Masateru, Sakurai Yojiro, Aoyama Takuo, Fujii Setsuro. Synthesis and structure-activity study of protease inhibitors. II. Amino and guanidine substituted naphthoates and tetrahydronaphthoates. Chem. Pharm. Bull. 32:1984;3968-3980.
14. Gabel′, 4-nitro-1-naphtylamina SchpeierZh. Obshch. Khim. 16, (1946) 2113, 2117; Chem. Abstr.; 1948; 156.
15. B. Caughey, D. Kocisko, A., S. Priola, in: H. Baker, R.M. Ridley (Ed.), A Methods in Molecular Medicine: Prion Disease, Humana press, Totowa, 1997, pp. 285-300.
16. Giaccone G., Canciani B., Puoti G., Rossi G., Goffredo D., Iussich S., Fociani P., Tagliavini F., Bugiani O. Creutzfeldt-Jakob disease: carnoy's fixative improves the immunoisotochemistry of the proteinasi K-resistant prion protein. Brain Pathol. 10:2000;31-37.